|N-(1,5-二甲基-3-氧代-2-苯基-2,3-二氢-1H-吡唑-4-基)-3-甲基-1-苯基-1H-噻吩并[2,3-c]吡唑-5-甲酰胺|CsnPharm

CAS No.: 306959-01-3

MYLS22 Catalog No. CSN28765

MYLS22 is a first-in-class small molecule-specific OPA1 inhibitor which inhibits tumor angiogenesis, impacts tumor growth and metastatization dependent on NFκB pathway.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述The inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1) is required for angiogenesis. In response to angiogenic stimuli, OPA1 levels rapidly increase to limit nuclear factor kappa-light-chain-enhancer of activated B cell (NFκB) signaling, ultimately allowing angiogenic genes expression and angiogenesis. Endothelial Opa1 is indeed required in an NFκB-dependent pathway essential for developmental and tumor angiogenesis, impacting tumor growth and metastatization. MYLS22 is a first-in-class and selective OPA1 inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice^[2]. The offspring from crosses of a constitutive knockout for the structural complex I component Ndufs4 (Ndufs4(-/-)), and of a muscle-specific conditional knockout for the complex IV assembly factor Cox15 (Cox15(sm/sm)), with Opa1 transgenic (Opa1(tg)) mice showed improved motor skills and respiratory chain activities compared to the naive, non-Opa1-overexpressing, models. While the amelioration was modest in Ndufs4(-/-)::Opa1(tg) mice, correction of cristae ultrastructure and mitochondrial respiration, improvement of motor performance and prolongation of lifespan were remarkable in Cox15(sm/sm)::Opa1(tg) mice. Mechanistically, respiratory chain supercomplexes were increased in Cox15(sm/sm)::Opa1(tg) mice, and residual monomeric complex IV was stabilized^[3]. Cardiac function and mitochondrial morphology were rescued by Oma1 deletion, which prevented OPA1 cleavage. Feeding mice a high-fat diet or ablating Yme1l in skeletal muscle restored cardiac metabolism and preserved heart function without suppressing mitochondrial fragmentation. Thus, unprocessed OPA1 is sufficient to maintain heart function, OMA1 is a critical regulator of cardiomyocyte survival, and mitochondrial morphology and cardiac metabolism are intimately linked^[4].
参考文献

[1] Herkenne S, Ek O, Zamberlan M, Pellattiero A, Chergova M, Chivite I, Novotná E, Rigoni G, Fonseca TB, Samardzic D, Agnellini A, Bean C, Di Benedetto G, Tiso N, Argenton F, Viola A, Soriano ME, Giacomello M, Ziviani E, Sales G, Claret M, Graupera M, Scorrano L. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. doi: 10.1016/j.cmet.2020.04.007. Epub 2020 Apr 20. PMID: 32315597.
[2] Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.
[3] Gabriele Civiletto,et al. Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. Cell Metab. 2015 Jun 2;21(6):845-54.
[4] Timothy Wai,et al. Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science. 2015 Dec 4;350(6265):aad0116.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2547 mL
- 11.2734 mL
- 22.5469 mL
- 5 mM
- 0.4509 mL
- 2.2547 mL
- 4.5094 mL
- 10 mM
- 0.2255 mL
- 1.1273 mL
- 2.2547 mL

技术信息

CAS号	306959-01-3	储存条件	粉末 Keep in dark place,Sealed in dry,Room Temperature 液体 -20°C:3-6 月 -80°C:12月
分子式	C24H21N5O2S	运输	蓝冰
分子量	443.52	别名

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

MYLS22 Catalog No. CSN28765

靶点选择性

请登录您的专属账户

确认信息